GlassScriptPhysician profile
William D Tutrone
NPI 1861643611
$5,658.78
in general payments reported to CMS, 2019-2025
27 companies · $818 in 2025
The $818 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $912 · 2020: $327 · 2021: $333 · 2022: $1,027 · 2023: $1,180 · 2024: $1,062 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,060.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $756.59 | 2019-2025 | |
| Janssen Biotech, INC. | $727.27 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $723.81 | 2020-2025 | Skyrizi, Rinvoq |
| Amgen INC. | $470.78 | 2021-2025 | Otezla |
| Lilly USA, LLC | $441.83 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $365.56 | 2022-2025 | Opzelura |
| Genzyme Corporation | $355.83 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $346.57 | 2019-2025 | Dupixent, Libtayo |
| Biofrontera INC. | $299.26 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $288.66 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $223.97 | 2023-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $112.35 | 2020-2024 | Duobrii, Siliq |
| Mayne Pharma Commercial LLC | $111.74 | 2019-2020 | |
| Smith+Nephew, INC. | $97.57 | 2019-2023 | Collagenase Santyl, Regranex, Grafix Pl |
| Organogenesis INC. | $77.28 | 2024-2025 | Affinity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $57.15 | 2022-2023 | Cimzia |
| Mission Pharmacal Company | $28.05 | 2022 | |
| Pfizer INC. | $23.82 | 2022 | |
| Sandoz INC. | $23.44 | 2023 | Hyrimoz |
| Vyne Pharmaceuticals INC. | $23.38 | 2020 | |
| Verrica Pharmaceuticals INC. | $23.25 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $16.28 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $14.77 | 2019 | |
| Genentech USA, INC. | $13.79 | 2019 | |
| Hartmann USA, INC. | $13.67 | 2025 | Zetuvit Plus 10x10 P10 |
| Galderma Laboratories, L.P. | $12.40 | 2019 | |
| Epi Health, LLC | $9.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Tutrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.